Pneumocystis Pneumonia is increasing in Immunocompromised Non-HIV Infected Patients. The effects and safety of caspofungin and corticosteroids is not certain in this population. All Immunocompromised Non-HIV patients with respiratory failure were randomized into caspofungin and non-caspofungin group and corticosteroids and non-steroids group. The major outcome is 28 day mortality, the second outcome are time of respiratory rate decreases to less than 25 breath per minute, body temperature lower than 37.3℃.

Start Date01 Nov 2015

Sponsor / Collaborator

Beijing Chao-Yang Hospital

100 Clinical Results associated with Sulfanilamide

100 Translational Medicine associated with Sulfanilamide

100 Patents (Medical) associated with Sulfanilamide

9,983

Literatures (Medical) associated with Sulfanilamide

11 Dec 2024·Journal of Biomolecular Structure and Dynamics

Acetylsalicylic acid-sulfa drugs conjugates as potential urease inhibitors and anti-inflammatory agents: bio-oriented drug synthesis, molecular docking, and dynamics simulation studies

Article

Author: Yousaf, Numan ; Imran, Muhammad ; Muddassar, Muhammad ; Asari, Asnuzilawati ; Hameed, Abdul ; Ahmed, Mahmood ; Abdul Qadir, Muhammad ; Ahmad, Saghir

To explore the new mode of action and reduce side effects, making conjugates of existing drugs is becoming an attractive tool in the realm of medicinal chemistry. In this work, we exploited this approach and synthesized new conjugates to assess their activities against the enzymes involved in different pathological conditions. Specifically, we design and synthesized conjugates involving acetylsalicylic acid and sulfa drugs, validating the newly crafted conjugates using techniques like IR, ¹HNMR, ¹³CNMR, and elemental analysis. These conjugates underwent assessment for their ability to inhibit cyclooxygenase-2 (COX-2), urease enzymes, and their anti-inflammatory potential. A competitive mode of urease inhibition was observed for acetylsalicylic acid conjugated with sulfanilamide, sulfacetamide, and sulfadiazine with IC₅₀ of 2.49 ± 0.35 µM, 6.21 ± 0.28 µM, and 6.57 ± 0.44 µM, respectively. Remarkably, the acetylsalicylic acid-sulfamethoxazole conjugate exhibited exceptional anti-inflammatory activity, effectively curtailing induced edema by 83.7%, a result akin to the reference anti-inflammatory drug indomethacin's performance (86.8%). Additionally, it demonstrated comparable COX-2 inhibition (75.8%) to the reference selective COX-2 inhibitor celecoxib that exhibited 77.1% inhibition at 10 µM concentration. To deepen our understanding, we employed molecular docking techniques to predict the binding interactions of competitive inhibitors with COX-2 and urease receptors. Additionally, MD simulations were carried out, confirming the stability of inhibitor-target complexes throughout the simulation period, devoid of significant conformational changes. Collectively, our research underscores the potential of coupling approved medicinal compounds to usher in novel categories of pharmacological agents, holding promise for addressing a wide spectrum of pathological disorders involving COX-2 and urease enzymes.Communicated by Ramaswamy H. Sarma.

01 Dec 2024·Applied Microbiology and Biotechnology

A novel Escherichia coli cell–based bioreporter for quantification of salicylic acid in cosmetics

Article

Author: Jang, Geupil ; Kim, Bong-Gyu ; Jeon, Yangwon ; Kim, Yeonhong ; Yoon, Youngdae

AbstractTranscription factor–based bioreporters have been extensively studied for monitoring and detecting environmental toxicants. In Escherichia coli, the multiple antibiotic resistance regulator (MarR) induces transcription upon binding to salicylic acid (SA). We generated SA-specific E. coli cell–based bioreporters utilizing the operator region of the mar operon and MarR as components of the reporter and sensing domains, respectively. Although bioreporters based on endogenous MarR and wild-type E. coli cells responded to SA, their sensitivity and selectivity were insufficient for practical sample monitoring. To improve these parameters, we genetically engineered host strains for optimal MarR expression, which enhanced the sensitivity of the biosensor to micromolar quantities of SA with increased selectivity. Under the optimized experimental conditions, the biosensor could quantify SA in environmental samples. For validation, the SA concentration in artificially contaminated SA-containing cosmetic samples was determined using the developed biosensor. Reliability assessment by comparing the concentrations determined using LC–MS/MS revealed > 90% accuracy of the bioreporters. Although bioreporters are not considered standard tools for environmental monitoring, bacterial cell–based bioreporters may serve as alternative tools owing to their affordability and simplicity. The SA biosensor developed in this study can potentially be a valuable tool for monitoring SA in environmental systems.Key points• SA-responsive bioreporter is generated by employing mar operon system in E. coli• SA specificity and selectivity were enhanced by genetic/biochemical engineering• The novel bioreporter would be valuable for SA monitoring in environmental systems

01 Dec 2024·Environmental Pollution

Nano boron carbide effectively boost Fenton-like performance of hematite mediated systems: Roles of hematite exposed facets and synergistic catalysis between Fe and B

Article

Author: Wang, Lianfeng ; Guo, Haiyan ; Han, Lei ; Yan, Song ; Luo, Qing ; Yu, Huali ; Jin, Xinxin ; Liu, Guangfei ; Zhang, Yulu

The inherent properties of exposed facets of iron minerals played key roles in heterogeneous reactions at the mineral interface, and the addition of co-catalysts has been elucidated to further enhance the reactions for contaminants degradation. Here, synergistic Fenton-like catalytic reactivity of different hematite dominant exposed facets ({001}, {012}, {100}, and {113}) with nano boron carbide (B₄C) was revealed. In 5 h, as compared with the cumulative •OH in the B₄C/H₂O₂ system (96.9 μM), while that in the {001}/B₄C/H₂O₂ system was decreased by 19.6%, those in the {012}/B₄C/H₂O₂, {100}/B₄C/H₂O₂, and {113}/B₄C/H₂O₂ systems were increased by 53.8%, 75.9%, and 84.0%, respectively. Significantly, {113}/B₄C/H₂O₂ system exhibited strong capability for degradation of a broad spectrum of organic pollutants, including typical phenol, endocrine disruptor (bisphenol A), antibiotic (sulfanilamide), dyes (Rhodamine B and methylene blue), and pesticide (atrazine). During the Fenton-like reactions, higher synergy factor, Fe(III)/Fe(II) cycling rate, and amount of Fe-O-B bond in the {113}/B₄C/H₂O₂ system were shown than those in other systems, thus exhibiting its desirable catalytic performance for •OH production and pollutants oxidation. Iron species and X-ray photoelectron spectroscopy (XPS) analyses indicated that B-B bond and interfacial suboxide boron (e.g., B-O) could provide electrons to facilitate Fe(III) reduction for boosting the Fe(III)/Fe(II) cycling. Density functional theory (DFT) results demonstrated the formation of Fe-O-B bond on hematite {113}, {100}, and {012} facets, which were beneficial to the breakage of O-O bond of bound H₂O₂ molecule and thus improved the generation of •OH. This study emphasized the essential role of B₄C in developing tailored hematite facets as a contaminant remediation substrate, and provided important insights into the design of efficient heterogeneous Fenton-like systems.

News (Medical) associated with Sulfanilamide

23 Jun 2022

·endpts.com

FDA warns Mexican glycerin manufacturer for refusing an inspection

A drug manufacturing facility in Mexico is drawing the ire of the FDA after it ignored the US regulator’s inspection requests and phone calls. According to the warning letter issued on June 13, Glicerinas Industriales refused a pre-announced inspection during a phone call with FDA prior to the inspection at the company’s facility in Zapopan, Mexico, a city next to Guadalajara, which was planned for May 16 to May 20. The company, which also goes by Glinsa, is a supplier of a wide range of drug ingredients, including glycerin, to manufacturers of finished drug products. These include manufacturers that distribute to the US. The letter made clear the importance of the inspection given that the use of glycerin contaminated with diethylene glycol (DEG) has resulted in various lethal poisoning incidents over the years in various countries. According to the FDA’s guidance on the subject from 2007, that regulator has received and continues to receive reports about fatal DEG poisoning of consumers who ingested medicinal syrups, such as cough syrup, that were manufactured with DEG-contaminated glycerin. According to the letter, the company’s drugs are now “adulterated” in that they have been manufactured, processed, packed or held in an establishment that delays, denies or limits an inspection, or refuses to permit entry or inspection. The FDA placed the company on Import Alert on June 9, and until the FDA is permitted to inspect the facility and enters compliance, they can withhold approval of any new applications or supplements listing it as a drug manufacturer. In addition, shipments of articles manufactured at Glicerinas Industriales into the US that appear to be adulterated are subject to being detained or refused admission. In 1937, an outbreak of DEG poisoning occurred in the US, which resulted from people ingesting an elixir of sulfanilamide that contained DEG as a solvent, resulting in 107 deaths, many of them children, which in part led to the Food Drug & Cosmetics Act to be passed. In late 1995 and early 1996, many children were admitted to hospitals in Port-au-Prince, Haiti, with sudden kidney failure, resulting in at least 80 fatalities, following similar poisoning.

27 Jul 2021

·www.globenewswire.com

Cidara Therapeutics to Present New Data for Rezafungin at

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International Society for Human and Animal Mycology (ISHAM) Asia Congress taking place virtually from August 6-8, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill patients. ISHAM Asia is a new conference aiming to increase opportunities for regional healthcare professionals and researchers and encourages their participation to interact with global leaders in the field of medical mycology. Presentation details are summarized below. Pre-Recorded Co-Sponsored Presentation followed by live Q&A: Title: Rezafungin: A novel, once-weekly echinocandin in phase 3 development for treatment and prevention of invasive fungal diseasePresenter: Taylor Sandison, Chief Medical Officer, Cidara TherapeuticsSession Date/Time: Friday, August 6, 2021 at 6:00 a.m. ET E-Poster Presentation:Title: Activity of rezafungin against clinical Candida and Aspergillus spp. isolates collected in Asia-Pacific (AP) countries (2014-2018)Presenter: Taylor Sandison, Chief Medical Officer, Cidara Therapeutics To register and view the full schedule, visit ISHAM Asia’s website here. Copies of the presentations will be made available on the Publications section of Cidara’s website. About RezafunginRezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial). About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit . INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Patrick BurseyLifeSci Communications(203) 430-9545pbursey@lifescicomms.com

30 Jun 2021

·www.globenewswire.com

Cidara Therapeutics to Present New Analyses for Rezafungin

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021. Rezafungin is a novel once-weekly echinocandin currently being studied in Phase 3 trials for the treatment and prevention of serious fungal infections in critically ill and cancer patients. Abstracts selected for presentation are summarized below. Oral Presentation: Title: Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Outcomes During Initial Days of Treatment Presenter: Alex Soriano, M.D., Ph.D., University of Barcelona Session Date/Time: Saturday, July 10, 2021 at 7:55 p.m. ET On-Demand e-Poster Presentations:Title: Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween®20Presenter: Jeffrey B Locke, Ph.D., Cidara Title: Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory ValuesPresenter: George R. Thompson III, M.D., University of California Davis Medical Center, Davis Title: A Multicenter Pharmacoepidemiologic Evaluation of Echinocandin UsePresenter: Jinhee Jo, Pharm.D., University of Houston To register and view the full schedule, visit ECCMID 2021’s website here. Copies of the presentations will be made available on the Publications section of Cidara’s website. About RezafunginRezafungin is a novel once weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial). About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit . INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Patrick BurseyLifeSci Communications(203) 430-9545pbursey@lifescicomms.com

100 Deals associated with Sulfanilamide

External Link

KEGG	Wiki	ATC	Drug Bank
D08543	Sulfanilamide	D06BA05 J01EB06	DB00259

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	CN	Shijiazhuang Heping Pharmaceutical Factory	01 Jan 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sulfanilamide

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation